Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538684 | 0.95 | MTNR1A (0.42) | MTNR1ANQO2NPC1RAB9AGPR84 | |
| SCHEMBL5543510 | 0.94 | SLC16A3 (0.41) | MTNR1ANQO2NPC1RAB9AGPR84 | |
| SCHEMBL5542952 | 0.94 | SLC16A3 (0.41) | MTNR1ANQO2NPC1RAB9AGPR84 | |
| SCHEMBL25888 | 0.90 | MTNR1A (0.45) | MTNR1ANQO2NPC1RAB9ATDP1 | |
| SCHEMBL29853 | 0.79 | NPC1 (0.54) | NPC1RAB9ATDP1CYP1A2CYP2C9 | |
| SCHEMBL9800436 | 0.78 | CYP1A2 (0.58) | MTNR1ANQO2GPR84TDP1MCL1 | |
| SCHEMBL5830948 | 0.78 | GPR84 (0.59) | MTNR1ANQO2GPR84TDP1MCL1 | |
| SCHEMBL2094192 | 0.77 | NQO2 (0.46) | MTNR1ANQO2GPR84TDP1MCL1 | |
| SCHEMBL143128 | 0.77 | MTNR1A (0.47) | MTNR1ANQO2GPR84TDP1MCL1 | |
| SCHEMBL2094194 | 0.77 | CYP1A2 (0.47) | MTNR1ANQO2GPR84TDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751827-B2 | Method for alkylation of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-09-05 | — | — | US | disclosed |
| US-20160009632-A1 | METHOD FOR ALKYLATION OF AMINES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-01-14 | — | — | US | disclosed |
| EP-2966057-A1 | METHOD FOR ALKYLATION OF AMINES | Takasago International Corporation (JP) | 2016-01-13 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-5432195-A | Anticholesterol | NIPPON SHINYAKU COMPANY LIMITED (JP) | 1995-07-11 | — | — | US | disclosed |
| EP-0601181-A1 | BENZOFURAN DERIVATIVE AND PHARMACEUTICAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MTNR1A 1560/4885NQO2 123/4885NPC1 2404/4885 |
| US-20160009632-A1 | METHOD FOR ALKYLATION OF AMINES | TAAR5, ADH5, ADH1A | MTNR1A 1990/4885NQO2 205/4885NPC1 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.